Drugs / Epratuzumab
Trials 27
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02306629 | Nov 2014 → Apr 2015 | systemic lupus erythematosus | UCB Biopharma S.P.R.L. | Completed | No outcome recorded |
| Phase 1 | NCT00054834 | Mar 2003 → ? | non-Hodgkin lymphoma | Gilead Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT00011908 | Feb 2001 → Jan 2003 | systemic lupus erythematosus | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT01449071 | Oct 2011 → Mar 2013 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 1/2 | NCT01279707 | Jan 2010 → Aug 2014 | B-cell acute lymphoblastic leukemia | Queen Mary University of London | Unknown | No outcome recorded |
| Phase 1/2 | NCT00098839 | Feb 2005 → Apr 2011 | childhood acute lymphoblastic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00061425 | Aug 2000 → Nov 2007 | B-cell non-Hodgkin lymphoma | Gilead Sciences | Completed | No outcome recorded |
| Phase 213 trials · 1 missed | ||||||
| Phase 2 | NCT01534403 | Jan 2012 → Feb 2015 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT01219816 | Nov 2010 → Nov 2016 | B-cell acute lymphoblastic leukemia | Nantes University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00945815 | Sep 2010 → Mar 2013 | leukemia | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 2 | NCT00941928 | Jul 2009 → May 2012 | childhood malignant neoplasm, leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00660881 | May 2008 → Dec 2011 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00553501 | Mar 2008 → Jul 2010 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00624351 | Jan 2008 → Aug 2009 | systemic lupus erythematosus | UCB Pharma | Completed | Missed primary |
| Phase 2 | NCT00383513 | Jun 2006 → Jan 2012 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00301821 | Jan 2006 → Oct 2008 | lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00113971 | Apr 2005 → Mar 2007 | systemic lupus erythematosus | UCB Pharma | Terminated | No outcome recorded |
| Phase 2 | NCT00113802 | Aug 2004 → Dec 2006 | Waldenstrom macroglobulinemia | Gilead Sciences | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00042913 | May 2002 → ? | lymphoma | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00044902 | — | non-Hodgkin lymphoma | Amgen | Completed | No outcome recorded |
| Phase 36 trials · 2 missed | ||||||
| Phase 3 | NCT01408576 | Jul 2011 → Feb 2016 | systemic lupus erythematosus | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT01262365 | Dec 2010 → May 2015 | systemic lupus erythematosus | UCB Pharma | Completed | Missed primary |
| Phase 3 | NCT01261793 | Dec 2010 → May 2015 | systemic lupus erythematosus | UCB Pharma | Completed | Missed primary |
| Phase 3 | NCT00382837 | Jan 2007 → ? | systemic lupus erythematosus | UCB Pharma | Withdrawn | No outcome recorded |
| Phase 3 | NCT00111306 | Jun 2005 → Mar 2007 | systemic lupus erythematosus | UCB Pharma | Terminated | No outcome recorded |
| Phase 3 | NCT00022685 | Sep 2001 → ? | lymphoma | Jonsson Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00398372 | Nov 2000 → Jun 2007 | Waldenstrom macroglobulinemia, diffuse large B-cell lymphoma, mantle cell lymphoma, marginal zone lymphoma +2 | Stanford University | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1/2 | NCT01354457 Background | Nov 2010 → Jun 2016 | acute lymphoblastic leukemia | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02577094 Background | ? → Jan 2017 | B-cell acute lymphoblastic leukemia | Nantes University Hospital | Withdrawn | No outcome recorded |
| Phase 3 | NCT01802814 Comparator | May 2014 → Jul 2023 | acute lymphoblastic leukemia | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00383214 Comparator | May 2005 → Mar 2007 | systemic lupus erythematosus | UCB Pharma | Terminated | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 32 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | epratuzumab | “hLL2 (epratuzumab)” NCT00054834 ↗ |
| Known as | hLL2 | “This study will examine the safety of a new genetically engineered antibody called hLL2 (epratuzumab) in patients with systemic lupus erythematosus (SLE).” NCT00011908 ↗ |
| Known as | Humanized LL2 IgG | “A Phase I Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Systemic Lupus Erythematosus” NCT00011908 ↗ |
| Action | Deplete | “indirect evidence suggests that the antibody is depleting target B lymphocytes” NCT00011908 ↗ |
| Modality | Monoclonal antibody | “hLL2 (epratuzumab), a humanized anti-CD22 monoclonal antibody” NCT00011908 ↗ |
| Route | Intravenous | “The drug is given through a catheter (small plastic tube) placed through a needle in an arm vein” NCT00011908 ↗ |
| Target | CD22 | “Epratuzumab (E) is an unlabeled anti-CD22 monoclonal antibody with efficacy in relapsed DLBCL.” PMID 21673350 ↗ Jun 2011 |